{"title":"Inclusion body myositis: an update.","authors":"Nicolaas C Anderson, Thomas E Lloyd","doi":"10.1097/BOR.0000000000001060","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>To review recent advances in our understanding of the epidemiology, pathophysiology, and management of inclusion body myositis (IBM).</p><p><strong>Recent findings: </strong>Recent epidemiologic studies have highlighted the morbidity and mortality associated with IBM, including the impact of dysphagia. Multiomic analyses of IBM tissues have identified new pathogenic pathways and biomarkers for use in clinical trials. New diagnostic criteria and outcome measures have been proposed to improve clinical trial design. Ongoing clinical trials are targeting T cells and autophagy.</p><p><strong>Summary: </strong>Improvements in our understanding of IBM pathogenesis are identifying new pathways and biomarkers that need validation in larger cohorts. Exercise remains the primary therapeutic modality available, and new treatment targets are needed.</p>","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":null,"pages":null},"PeriodicalIF":5.2000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/BOR.0000000000001060","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose of review: To review recent advances in our understanding of the epidemiology, pathophysiology, and management of inclusion body myositis (IBM).
Recent findings: Recent epidemiologic studies have highlighted the morbidity and mortality associated with IBM, including the impact of dysphagia. Multiomic analyses of IBM tissues have identified new pathogenic pathways and biomarkers for use in clinical trials. New diagnostic criteria and outcome measures have been proposed to improve clinical trial design. Ongoing clinical trials are targeting T cells and autophagy.
Summary: Improvements in our understanding of IBM pathogenesis are identifying new pathways and biomarkers that need validation in larger cohorts. Exercise remains the primary therapeutic modality available, and new treatment targets are needed.
综述的目的：回顾我们对包涵体肌炎（IBM）的流行病学、病理生理学和治疗方法的最新研究进展：最近的流行病学研究强调了与包涵体肌炎相关的发病率和死亡率，包括吞咽困难的影响。对 IBM 组织进行的多组学分析发现了新的致病途径和生物标记物，可用于临床试验。为改进临床试验设计，提出了新的诊断标准和结果测量方法。目前正在进行的临床试验以 T 细胞和自噬为目标。摘要：我们对 IBM 发病机制的认识有所提高，发现了新的发病途径和生物标志物，需要在更大的群体中进行验证。运动仍是现有的主要治疗方式，但需要新的治疗目标。
期刊介绍：
A high impact review journal which boasts an international readership, Current Opinion in Rheumatology offers a broad-based perspective on the most recent and exciting developments within the field of rheumatology. Published bimonthly, each issue features insightful editorials and high quality invited reviews covering two or three key disciplines which include vasculitis syndromes, medical physiology and rheumatic diseases, crystal deposition diseases and rheumatoid arthritis. Each discipline introduces world renowned guest editors to ensure the journal is at the forefront of knowledge development and delivers balanced, expert assessments of advances from the previous year.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
